YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
The available CDE acceptance records list 389 drug applications between 12 November 2026 and 18 November 2026 (data as of 23 November 2026). Of these, generic applications numbered 68, covering 47 drug names.
2026/11/12 – 2026/11/18
- New acceptances this week
- 389
- Drugs with new generic filings (by drug name, de-duplicated)
- 47
- Accepted this week, now under review
- 389
DefinitionAcceptance numbers accepted this week that are still on CDE's under-review list at the data cut-off; counted by acceptance date.
Names with a public page are linked.
New acceptances this week
By application type and drug type
389filings, 68 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 203 |
| New drug | 80 |
| Generic | 68 |
| Import | 27 |
| Import re-registration | 6 |
| Unspecified | 5 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 219 |
| TCM | 96 |
| Therapeutic biologic | 63 |
| Biologic | 6 |
| Prophylactic biologic | 5 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
47 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | Polyvinyl Alcohol Eye Drops | 3 | 2 | 26 |
| 2 | Mirogabalin Besilate Tablets | 3 | 2 | 64 |
| 3 | Ambroxol Hydrochloride Oral Solution | 3 | 1 | 49 |
| 4 | 西诺氨酯片 · No verified English name | 3 | 1 | 23 |
| 5 | Tafluprost Eye Drops | 2 | 2 | 3 |
| 6 | Rosuvastatin Calcium and Ezetimibe Tablets (I) | 2 | 2 | 7 |
| 7 | Trazodone Hydrochloride Sustained-release Tablets | 2 | 2 | 22 |
| 8 | Buprenorphine Hydrochloride and Naloxone Hydrochloride Sublingual Tablets | 2 | 1 | 2 |
| 9 | 二硫化硒洗剂 · No verified English name | 2 | 1 | 16 |
| 10 | Dotinurad Tablets | 2 | 1 | 56 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
244 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | Henan Pu Rui Pharma Co., Ltd. romanized | 14 | 8 | 0 |
| 2 | Eli Lilly and Company | 7 | 3 | 0 |
| 3 | CISEN PHARMACEUTICAL CO., LTD. | 6 | 3 | 3 |
| 4 | Novo Nordisk A/S | 6 | 1 | 0 |
| 5 | Shandong Bu Zhang Pharmaceutical Co., Ltd. romanized | 5 | 5 | 0 |
| 6 | Boehringer Ingelheim International GmbH | 5 | 2 | 0 |
| 7 | Beijing Tong Ren Tang Co., Ltd. Tong Ren Tang Pharmaceutical Factory romanized | 4 | 2 | 0 |
| 8 | Takeda Manufacturing Austria AG | 4 | 1 | 0 |
| 9 | Terumo Corporation Kofu Factory | 4 | 1 | 0 |
| 10 | Zhongshan Wanhan Pharmaceuticals Co., Ltd. | 4 | 1 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Based on changes in CDE's under-review list
- Entered review this week
- 419
- Left the under-review list this week
- 729
Of these, NMPA published approval-document delivery for 366 (including 358 supplemental applications, not counted as new marketing approvals) and notification delivery for 22; the outcome of the other 341 is to be checked.
Most filings leaving review, by company
| # | Company (first applicant) | Filings | Drugs |
|---|---|---|---|
| 1 | Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized | 13 | 3 |
| 2 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd. | 10 | 4 |
| 3 | Mu Dan Jiang Ling Tai Pharma Co., Ltd. romanized | 9 | 9 |
| 4 | AbbVie Inc. | 8 | 1 |
| 5 | Luo Yang Yi Long Pharma Co., Ltd. romanized | 7 | 7 |
| 6 | Shaanxi Dong Tai Pharmaceutical Co., Ltd. romanized | 7 | 7 |
| 7 | Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 7 | 6 |
| 8 | Eli Lilly and Company | 7 | 2 |
| 9 | Novartis Pharma AG | 6 | 4 |
| 10 | Guangdong Tai En Kang Pharmaceutical Factory Co., Ltd. romanized | 6 | 2 |
Most filings entering review, by company
| # | Company (first applicant) | Filings | Drugs |
|---|---|---|---|
| 1 | Henan Pu Rui Pharma Co., Ltd. romanized | 14 | 8 |
| 2 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd. | 7 | 3 |
| 3 | Eli Lilly and Company | 6 | 3 |
| 4 | CISEN PHARMACEUTICAL CO., LTD. | 6 | 3 |
| 5 | Novo Nordisk A/S | 6 | 1 |
| 6 | Suzhou Ya Sheng Pharma Co., Ltd. romanized | 6 | 1 |
| 7 | Shandong Bu Zhang Pharmaceutical Co., Ltd. romanized | 5 | 5 |
| 8 | Anhui Sheng Jing Cheng Hui Yao Pharma Co., Ltd. romanized | 5 | 3 |
| 9 | Boehringer Ingelheim International GmbH | 5 | 2 |
| 10 | Beijing Tong Ren Tang Co., Ltd. Tong Ren Tang Pharmaceutical Factory romanized | 4 | 2 |
DefinitionEntered review = acceptance numbers first listed on CDE's under-review list this week, excluding numbers already listed on the record start date (2026/10/22). Left review = acceptance numbers last listed this week and no longer listed at the data cut-off; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.
Class 3 and new-drug acceptances
119 this week
| Accepted | Drug | Applicants |
|---|---|---|
| 2026/11/18Generic · Class 3 | 二硫化硒洗剂 · No verified English nameCYHS2602839 | Anhui Tai Du Biopharmaceuticals Technology Co., Ltd. romanized; Yu Song Yuan Pharma Co., Ltd. romanized |
| 2026/11/18Generic · Class 3 | 二硫化硒洗剂 · No verified English nameCYHS2602838 | Anhui Tai Du Biopharmaceuticals Technology Co., Ltd. romanized; Yu Song Yuan Pharma Co., Ltd. romanized |
| 2026/11/18New drug · Class 1.1 | 龙藤颗粒 · No verified English nameCXZL2600116 | Heilongjiang Sheng Ji Ren Pharma Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | 格斯泮妥塔单抗注射液 · No verified English nameCXSS2600190 | Ming Ji Biopharmaceutical (Beijing) Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | LET003注射液 · No verified English nameCXSL2601284 | He Bo Pharmaceuticals (Shanghai) Co., Ltd. romanized |
| 2026/11/18New drug · Class 2.4 | 注射用重组A型肉毒毒素 · No verified English nameCXSL2601283 | Jiangsu Yao Hai Nuo Xin Bio Technology Co., Ltd. romanized; Yao Hai Nuo Xin Bio Technology (Wuhan) Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | 注射用GB268 · No verified English nameCXSL2601282 | Yi Teng Pharmaceuticals (Zhuhai) Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | ALC01细胞注射液 · No verified English nameCXSL2601281 | Ai Kai Li Yuan Bio Technology (Shanghai) Co., Ltd. romanized |
| 2026/11/18New drug · Class 2.3 | EP-0170T(Ⅰ) · No verified English nameCXHS2600154 | Chengdu Shuo De Pharma Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | TER-2013片 · No verified English nameCXHL2601452 | Bai Ji Shen Zhou (Shanghai) Bio Technology Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | TER-2013片 · No verified English nameCXHL2601451 | Bai Ji Shen Zhou (Shanghai) Bio Technology Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | BG-75202片 · No verified English nameCXHL2601450 | Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | BG-75202片 · No verified English nameCXHL2601449 | Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | BG-75202片 · No verified English nameCXHL2601448 | Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | MDN003注射液 · No verified English nameCXHL2601447 | Mai De Nuo He Pharmaceuticals Technology (Sichuan) Co., Ltd. romanized |
| 2026/11/17Import · Class 1 | LUM-201胶囊 · No verified English nameJXHL2600517 | Lumos Pharma LLC; ICON Clinical Research (Beijing No. 2) Co. Ltd. |
| 2026/11/17Import · Class 1 | LUM-201胶囊 · No verified English nameJXHL2600516 | Lumos Pharma LLC; ICON Clinical Research (Beijing No. 2) Co. Ltd. |
| 2026/11/17Import · Class 1 | LUM-201胶囊 · No verified English nameJXHL2600515 | Lumos Pharma LLC; ICON Clinical Research (Beijing No. 2) Co. Ltd. |
| 2026/11/17Generic · Class 3 | 恩那度司他片 · No verified English nameCYHS2602837 | Shandong Loncom Pharmaceutical Co., Ltd. |
| 2026/11/17Generic · Class 3 | 恩那度司他片 · No verified English nameCYHS2602836 | Shandong Loncom Pharmaceutical Co., Ltd. |
| 2026/11/17Generic · Class 3 | 血管紧张素Ⅱ注射液 · No verified English nameCYHS2602828 | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD |
| 2026/11/17New drug · Class 1 | XKH001注射液 · No verified English nameCXSL2601280 | Xin Kang He Biopharmaceuticals (Beijing) Co., Ltd. romanized; Beijing Xin Kang He Biopharmaceuticals Technology Co., Ltd. romanized |
| 2026/11/17New drug · Class 1 | DC01注射液 · No verified English nameCXSL2601279 | Chengdu Bo An Zhi Yan Xi Bao Bio Technology Co., Ltd. romanized; Sichuan Zhong Ke Ding Yao Xi Bao Technology Co., Ltd. romanized |
| 2026/11/17New drug · Class 1 | PTT-936口服冻干粉 · No verified English nameCXHL2601446 | Beijing Yan Ming Bio Technology Co., Ltd. romanized |
| 2026/11/17New drug · Class 2.1; 2.2; 2.4 | HW-N2001注射液 · No verified English nameCXHL2601445 | HARWAY PHARMA CO.,LTD. |
| 2026/11/17New drug · Class 1 | ZL-69胶囊 · No verified English nameCXHL2601444 | Chengdu Ze Ling Biopharmaceuticals Technology Co., Ltd. romanized |
| 2026/11/17New drug · Class 1 | ZL-69胶囊 · No verified English nameCXHL2601443 | Chengdu Ze Ling Biopharmaceuticals Technology Co., Ltd. romanized |
| 2026/11/17New drug · Class 1 | ZL-69胶囊 · No verified English nameCXHL2601442 | Chengdu Ze Ling Biopharmaceuticals Technology Co., Ltd. romanized |
| 2026/11/16Import · Class 1 | Zenagamtide片 · No verified English nameJXSL2600322 | Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd |
| 2026/11/16Import · Class 1 | Zenagamtide片 · No verified English nameJXSL2600321 | Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd |
89 more not listed (at most 30 rows).
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.